SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Emmaus Life Sciences, Inc. – ‘10-K’ for 9/30/15 – ‘R12’

On:  Tuesday, 1/5/16, at 5:13pm ET   ·   For:  9/30/15   ·   Accession #:  1615774-16-3804   ·   File #:  1-35527

Previous ‘10-K’:  ‘10-K/A’ on 1/23/15 for 9/30/14   ·   Next:  ‘10-K’ on 12/22/16 for 9/30/16   ·   Latest:  ‘10-K’ on 3/31/23 for 12/31/22

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/05/16  Emmaus Life Sciences, Inc.        10-K        9/30/15   77:6.5M                                   S2 Filings LLC/FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    869K 
 2: EX-3.1.3    Articles of Incorporation/Organization or Bylaws    HTML     26K 
 3: EX-10.25    Material Contract                                   HTML     72K 
 4: EX-10.26    Material Contract                                   HTML     29K 
 5: EX-23.1     Consent of Experts or Counsel                       HTML     21K 
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     27K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     26K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     22K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     22K 
16: R1          Document and Entity Information                     HTML     50K 
17: R2          Consolidated Balance Sheets                         HTML    103K 
18: R3          Consolidated Balance Sheets (Parenthetical)         HTML     40K 
19: R4          Consolidated Statements of Operations               HTML     84K 
20: R5          Consolidated Statements of Changes in               HTML     58K 
                Stockholders' Deficit                                            
21: R6          Consolidated Statements of Cash Flows               HTML    112K 
22: R7          Nature of Operations                                HTML     39K 
23: R8          Summary of Significant Accounting Policies          HTML     84K 
24: R9          Discontinued Operations                             HTML     45K 
25: R10         Convertible Debt and Equity Financings              HTML     52K 
26: R11         Derivative Liabilities                              HTML     38K 
27: R12         Stockholders' Deficit                               HTML    121K 
28: R13         Income Taxes                                        HTML     46K 
29: R14         Related Party Transactions                          HTML     66K 
30: R15         Loss Per Share                                      HTML     41K 
31: R16         Commitments and Contingent Liabilities              HTML     50K 
32: R17         Significant Customers                               HTML     26K 
33: R18         Subsequent Events                                   HTML     61K 
34: R19         Summary of Significant Accounting Policies          HTML    127K 
                (Policies)                                                       
35: R20         Summary of Significant Accounting Policies          HTML     51K 
                (Tables)                                                         
36: R21         Discontinued Operations (Tables)                    HTML     43K 
37: R22         Convertible Debt and Equity Financings (Tables)     HTML     41K 
38: R23         Derivative Liabilities (Tables)                     HTML     34K 
39: R24         Stockholders' Deficit (Tables)                      HTML    101K 
40: R25         Income Taxes (Tables)                               HTML     44K 
41: R26         Loss Per Share (Tables)                             HTML     38K 
42: R27         Commitments and Contingent Liabilities (Tables)     HTML     35K 
43: R28         Subsequent Events (Tables)                          HTML     57K 
44: R29         Nature of Operations (Details Narrative)            HTML     48K 
45: R30         Summary of Significant Accounting Policies          HTML     30K 
                (Details)                                                        
46: R31         Summary of Significant Accounting Policies          HTML     34K 
                (Details 1)                                                      
47: R32         Summary of Significant Accounting Policies          HTML     61K 
                (Details Narrative)                                              
48: R33         Discontinued Operations (Details)                   HTML     41K 
49: R34         Discontinued Operations (Details 1)                 HTML     37K 
50: R35         Convertible Debt and Equity Financings (Details)    HTML     71K 
51: R36         Convertible Debt and Equity Financings (Details     HTML    110K 
                Narrative)                                                       
52: R37         Derivative Liabilities (Details)                    HTML     30K 
53: R38         Derivative Liabilities (Details Narrative)          HTML     58K 
54: R39         Stockholders' Deficit (Details)                     HTML     31K 
55: R40         Stockholders' Deficit (Details 1)                   HTML     43K 
56: R41         Stockholders' Deficit (Details 2)                   HTML     94K 
57: R42         Stockholders' Deficit (Details 3)                   HTML     44K 
58: R43         Stockholders' Deficit (Details 4)                   HTML     56K 
59: R44         Stockholders' Deficit (Details Narrative)           HTML     69K 
60: R45         Stockholders' Deficit (Details Narrative 1)         HTML    136K 
61: R46         Stockholders' Deficit (Details Narrative 2)         HTML     44K 
62: R47         Income Taxes (Details)                              HTML     39K 
63: R48         Income Taxes (Details 1)                            HTML     43K 
64: R49         Income Taxes (Details Narrative)                    HTML     27K 
65: R50         Related Party Transactions (Details Narrative)      HTML    171K 
66: R51         Related Party Transactions (Details Narrative 1)    HTML    198K 
67: R52         Loss Per Share (Details)                            HTML     54K 
68: R53         Commitments and Contingent Liabilities (Details)    HTML     57K 
69: R54         Commitments and Contingent Liabilities (Details     HTML     53K 
                Narrative)                                                       
70: R55         Significant Customers (Details Narrative)           HTML     31K 
71: R56         Subsequent Events (Details)                         HTML     40K 
72: R57         Subsequent Events (Details 1)                       HTML     38K 
73: R58         Subsequent Events (Details 2)                       HTML     37K 
74: R59         Subsequent Events (Details Narrative)               HTML     60K 
76: XML         IDEA XML File -- Filing Summary                      XML    131K 
75: EXCEL       IDEA Workbook of Financial Reports                  XLSX     89K 
10: EX-101.INS  XBRL Instance -- cnso-20150930                       XML   1.83M 
12: EX-101.CAL  XBRL Calculations -- cnso-20150930_cal               XML    157K 
13: EX-101.DEF  XBRL Definitions -- cnso-20150930_def                XML    752K 
14: EX-101.LAB  XBRL Labels -- cnso-20150930_lab                     XML   1.02M 
15: EX-101.PRE  XBRL Presentations -- cnso-20150930_pre              XML    963K 
11: EX-101.SCH  XBRL Schema -- cnso-20150930                         XSD    163K 
77: ZIP         XBRL Zipped Folder -- 0001615774-16-003804-xbrl      Zip    152K 


‘R12’   —   Stockholders’ Deficit


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v3.3.1.900
STOCKHOLDERS' DEFICIT
12 Months Ended
Stockholders' Equity Note [Abstract]  
STOCKHOLDERS' DEFICIT
6. STOCKHOLDERS’ DEFICIT

 

Common and Preferred Stock

  

As of September 30, 2015, the Company is authorized to issue 195,000,000 shares of stock, of which 180,000,000 are Common Stock; the remaining 15,000,000 shares, with a par value of $0.001 per shares are blank-check preferred stock which the Board is expressly authorized to issue without shareholder approval, for one or more series of preferred stock and, with respect to each such series, to fix the number of shares constituting such series and the designation of such series, the voting powers, if any, of the shares of such series, and the preferences and relative, participating, optional or other special rights, if any, and any qualifications, limitations or restrictions thereof, of the shares of such series. The powers, preferences and relative, participating, optional and other special rights of each series of preferred stock, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding.

 

At the annual meeting held on October 28, 2015, shareholders approved to amend the Company’s Charter in order to increase the number of shares of Common Stock authorized for issuance under the Charter from 180,000,000 to 500,000,000 shares.

 

As of September 30, 2015, 102,417,409 shares of Common Stock were issued and outstanding. No shares of preferred stock were issued or outstanding.

 

From October 4, 2013, through July 23, 2014, 27 accredited investors purchased an aggregate of 6,940,000 shares of Common Stock, at a price of $0.25 per share pursuant to private placements. The Company received gross aggregate cash proceeds of $1,735,000. (Refer to Note 8. Related Party Transactions)

 

Between November 11, 2013, and December 20, 2013, the Company issued an aggregate of 1,446,380 shares of its Common Stock valued at $361,500, as full and complete settlement of trade payables totaling an aggregate $1,466,800 owed to two creditors who are also accredited investors. As a result of this transaction the Company recorded a gain on extinguishment of debt of $1,105,200.

 

On January 29, 2014 and June 20, 2014, placement agent warrants to purchase in aggregate 608,309 shares of Common Stock with a price of $0.04718 per share were exercised on a net basis resulting in the issuance of 564,467 shares of Common Stock.

 

On March 21, 2014, the Board resolved to amend the Company’s Charter in order to increase the number of shares of Common Stock authorized for issuance under the Charter from 150,000,000 to 180,000,000. This amendment to the Charter was approved by more than 65% of the stockholders eligible to vote at the annual meeting of stockholders held on May 13, 2014.

 

On September 3, 2015, the Board resolved to amend the Company’s Charter again in order to further increase the number of shares of Common Stock authorized for issuance under the Charter from 180,000,000 to 500,000,000. This amendment to the Charter was also approved by more than 65% of the stockholders eligible to vote at the annual meeting of stockholders held on October 28, 2015. (Refer to Note 12. Subsequent Events)

 

On August 20, 2015, the Board approved an award of 750,000 shares of the Company's restricted Common Stock to Dr. Smith in connection with her appointment as Chairman of the Company's Board. These shares, which are fully vested, were valued at $0.055 per share, the closing price of the shares on the day of grant, and were valued in aggregate at $41,250. The issuance of the shares was processed on October 30, 2015.

 

Stock-Option Plans

 

On August 3, 2006, CNS California adopted the CNS California 2006 Stock Incentive Plan (the “2006 Plan”). The 2006 Plan provides for the issuance of awards in the form of restricted shares, stock options (which may constitute incentive stock options (ISO) or non-statutory stock options (NSO), stock appreciation rights and stock unit grants to eligible employees, directors and consultants and is administered by the Board. A total of 667,667 shares of stock were ultimately reserved for issuance under the 2006 Plan. As of September 30, 2014, 70,825 options were exercised and there were 501,924 options and 6,132 restricted shares outstanding under the amended 2006 Plan leaving 87,786 shares which will not be issued as the 2006 Plan has been frozen. The outstanding options have exercise prices to purchase shares of Common Stock ranging from $3.60 to $32.70.

 

On March 22, 2012, our Board approved the MYnd Analytics, Inc. 2012 Omnibus Incentive Compensation Plan (the “2012 Plan”), reserved 333,334 shares of stock for issuance and on December 10, 2012, the Board approved the amendment of the 2012 Plan to increase the shares authorized for issuance from 333,334 shares to 5,500,000 shares. On March 26, 2013, the Board further approved the amendment of the 2012 Plan to increase the shares authorized for issuance from 5,500,000 shares to 15,000,000 shares. The 2012 Plan, as amended, was approved by our stockholders at the 2013 annual meeting held on May 23, 2013.

 

On October 8, 2013, the Board granted to the Company’s two executive officers and two senior managers (collectively, the “Managers”) options to purchase shares of its Common Stock pursuant to the 2012 Omnibus Incentive Compensation Plan, as amended (the “2012 Plan”), at an exercise price of $0.25 per share as follows: George Carpenter 435,000 shares, Paul Buck 470,000 shares, Stewart Navarre 385,000 shares and Brian MacDonald 310,000. These options vested pro-rata over 12 months starting from the date of grant. The four managers agreed to forego a portion of their salaries in fiscal year 2014 as follows: George Carpenter $98,000, Paul Buck $106,500, Stewart Navarre $83,600 and Brian MacDonald $66,700. These executive officers and managers will be paid out of the salaries which were earned and accrued during fiscal years 2012 and 2013. The accruals to be paid out are equivalent to the fiscal year 2014 salaries that each of the executive officers and managers agreed to forego in lieu of receiving options.

 

On November 8, 2013, the Board granted 700,000 options to purchase shares of its Common Stock pursuant to the 2012 Plan, at an exercise price of $0.25 per share to select consultants and staff, excluding the managers. The staff options vest evenly over 48 months starting on the date of grant; consultant options vest evenly over 36 months starting on the date of grant.

 

On July 31, 2014, the Board granted 425,000 options to purchase shares of its Common Stock pursuant to the 2012 Plan, at an exercise price of $0.26 per share to select consultants. These options vest evenly over 36 months starting on the date of grant.

 

On January 8, 2015, the Board granted an option to purchase 250,000 shares of its Common Stock pursuant to the 2012 Plan, at an exercise price of $0.25 per share to a consultant. The option vesting is contingent upon the achievement of agreed upon goals.

 

On August 20, 2015, August 20, 2015, the Board approved an award of options to purchase 250,000 shares of the Company’s common stock for each of the Company's directors, for an aggregate grant of 1,750,000 options. The options are exercisable at a price per share of $0.055, the closing price of the Company's common stock on the date of grant, and will vest pro-rata over 36 months.

 

As of September 30, 2015, 70,825 options had been exercised and 501,924 options and 6,132 restricted shares were outstanding under the amended 2006 Plan leaving 87,786 shares which management does not believe will ever be issued as the 2006 Plan is frozen. Options to purchase 13,728,087 shares of Common Stock and 750,000 restricted shares remain outstanding under the 2012 Plan. None of these options have been exercised, leaving 521,913 options available for issuance.

 

Stock-based compensation expenses are generally recognized over the employees’ or service provider’s requisite service period, generally the vesting period of the award. Stock-based compensation expense included in the accompanying statements of operations for the year ended September 30, 2015 and 2014 is as follows:   

 

    September 30  
    2015     2014  
Cost of Neurometric Services revenues   $     $ 5,100  
Research     41,600       65,500  
Product Development     52,300       249,700  
Sales and marketing     81,600       87,700  
General and administrative     66,200       600,700  
Total   $ 241,700     $ 1,008,700  

 

Total unrecognized compensation as of September 30, 2015 amounted to $216,300.

 

A summary of stock option activity is as follows:

 

    Number of 
Shares
    Weighted
Average 
Exercise
Price
 
Outstanding at September 30, 2013     9,749,594     $ 1.00  
Granted     2,725,000       0.25  
Exercised     -          
Forfeited     (57,095 )     12.67  
Outstanding at September 30, 2014     12,417,499     $ 0.84  
Granted     2,000,000       0.08  
Exercised     -       -  
Forfeited     (187,488 )     0.11  
Outstanding at September 30, 2015     14,230,011     $ 0.75  

 

Following is a summary of the status of options outstanding at September 30, 2015:

 

Exercise
Price ($)
    Number
of Shares
    Expiration
Date
  Weighted Average
Exercise Price ($)
 
                         
$ 0.055       1,750,000     08/2025   $ 0.055  
  0.04718       8,795,308     12/2022 – 01/2023     0.04718  
  0.25       2,715,109     03/2023 – 01/2025     0.25  
  0.26       425,000     07/2024     0.26  
  3.00       42,670     03/2022     3.00  
  3.60       28,648     08/2016     3.60  
  3.96       32,928     08/2016     3.96  
  9.00       4,525     11/2016     9.00  
  12.00       28,535     03/2019 – 07/2020     12.00  
  14.10       10,000     03/2021     14.10  
  15.30       1,373     09/2018     15.30  
  16.50       262,441     03/2020     16.50  
  17.70       953     08/2016     17.70  
  24.00       4,667     12/2017     24.00  
  26.70       32,297     09/2017     26.70  
  28.80       11,767     04/2018     28.80  
$ 32.70       83,790     08/2017   $ 32.70  
  Total       14,230,011     Average   $ 0.75  

 

Warrants to Purchase Common Stock

 

The warrant activity for the period starting October 1, 2013, through September 30, 2015, is described as follows:

 

    Number of 
Shares
    Weighted
Average 
Exercise Price
 
Outstanding at October 1, 2013     1,497,556     $ 3.03  
Granted     152,200       0.27  
Exercised     (608,309 )     0.04718  
Expired     (226,703 )     9.14  
Outstanding at September 30, 2014     814,744     $ 3.07  
Granted     200,000       0.25  
Exercised            
Expired     (233,220 )     9.14  
Outstanding at September 30, 2015     781,524     $ 0.53  

 

Following is a summary of the status of warrants outstanding at September 30, 2015:

 

Exercise
Price
    Number
of Shares
    Expiration
Date
  Weighted Average
Exercise Price
 
                         
$ 0.04718       38,152     03/2018   $ 0.04718  
  0.25       332,200     04/2016 – 07/2017     0.25  
  0.275       324,000     06/2018 – 03/2019     0.275  
  1.00       67,170     10/2015 – 01/2017     1.00  
  7.50       3,334     05/2016     7.50  
$ 9.00       16,668     07/2017     9.00  
  Total       781,524         $ 0.53  

 

On March 22, 2014, a warrant to purchase 120,000 shares of Common Stock at an exercise price of $0.275 per share was issued to Monarch Capital who acted as placement agents in raising $300,000 from 11 accredited investors who purchased restricted Common Stock in private placement agreements dated October 2, 2013 and January 8, 2014.

 

Also on March 22, 2014, a warrant to purchase 32,200 shares of Common Stock at an exercise price of $0.25 per share was issued to D&D Securities, Inc. who acted as placement agents in raising $115,000 from three accredited investors who purchased restricted Common Stock in private placement agreements dated January 8, 2014.

 

On August 1, 2014, a warrant to purchase 200,000 shares of Common Stock at an exercise price of $0.25 per share was issued to Red Chip Companies, Inc. pursuant to an investor relations services agreement.

 

At September 30, 2015, there were warrants outstanding to purchase 781,524 shares of the Company’s Common Stock. The exercise price of the outstanding warrants range from $0.04718 to $9.00 with a weighted average exercise price of $0.53. The warrants expire at various times starting 2015 through 2019.

 

Please refer to Note 12. Subsequent Events for Note activity after September 30, 2015, regarding issuances of warrants. 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:1/5/16
10/30/15
10/28/158-K,  DEF 14A
For Period end:9/30/158-K,  CORRESP,  NT 10-K,  PRER14A
9/3/158-K
8/20/153,  4,  8-K
1/8/15
9/30/1410-K,  10-K/A,  D
8/1/14
7/31/14
7/23/14
6/20/14
5/13/14DEF 14A
3/22/14
3/21/14
1/29/14
1/8/14
12/20/13
11/11/13
11/8/13
10/8/134
10/4/138-K
10/2/13
10/1/13
9/30/1310-K,  10-K/A,  ARS
5/23/134,  8-K,  DEF 14A
3/26/138-K
12/10/128-K
3/22/123,  8-K
8/3/06
 List all Filings 
Top
Filing Submission 0001615774-16-003804   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 27, 11:08:59.1am ET